This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Single dose of mRNA-1345 vaccine safe, effective against RSV in seniors

Single dose of mRNA-1345 vaccine safe, effective against RSV in seniors

A single dose of mRNA-1345 vaccine is safe and results in lower incidence of respiratory syncytial virus (RSV)-associated disease in older patients, according to a study published in the Dec. 14 issue of the New England Journal of Medicine.

Eleanor Wilson, M.D., from Moderna in Cambridge, Massachusetts, and colleagues conducted a randomized, phase 2 to 3 trial in which adults aged 60 years of age or older were randomly assigned to receive one dose of mRNA-1345 (50 μg; 17,793 participants) or placebo (17,748 participants).

Participants were followed for a median of 112 days. The researchers found that was 83.7 and 82.4 percent against RSV-associated lower respiratory tract disease with at least two signs or symptoms and against the disease with at least three signs or symptoms, respectively. Vaccine efficacy against RSV-associated acute respiratory disease was 68.4 percent. Protection was seen against RSV subtypes A and B and was mainly consistent across subgroups defined according to age and coexisting conditions. Compared with those in the , participants in the mRNA-1345 group had a of solicited local adverse reactions (58.7 versus 16.2 percent) and of systemic adverse reactions (47.7 versus 32.9 percent); most reactions were mild-to-moderate and transient. Overall, 2.8 percent of each trial group had serious adverse events.

"This 2 to 3 efficacy trial showed that a single 50-μg dose of the mRNA-1345 vaccine in adults 60 years of age or older was efficacious against a spectrum of RSV-confirmed respiratory disease," the authors write

The study was funded by Moderna, the manufacturer of the mRNA-1345 vaccine.

More information: Eleanor Wilson et al, Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults, New England Journal of Medicine (2023). DOI: 10.1056/NEJMoa2307079

Amanda C. Cohn et al, Continued Progress in the Development of Safe and Effective RSV Immunizations, New England Journal of Medicine (2023). DOI: 10.1056/NEJMe2311862

Journal information: New England Journal of Medicine

Copyright © 2023 HealthDay. All rights reserved.

Citation: Single dose of mRNA-1345 vaccine safe, effective against RSV in seniors (2023, December 14) retrieved 22 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Ad26.RSV.preF-RSV preF protein vaccine immunogenic in seniors


Feedback to editors